Document Detail


Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes.
MedLine Citation:
PMID:  25368104     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: To assess the relationship between second and third trimester glycemic control and adverse outcomes in pregnant women with type 1 diabetes, as uncertainty exists about optimum glycemic targets.
RESEARCH DESIGN AND METHODS: Pregnancy outcomes were assessed prospectively in 725 women with Type 1 diabetes from the Diabetes and Pre-eclampsia Intervention Trial. HbA1c (A1C) values at 26 and 34 weeks' gestation were categorised into 5 groups; the lowest, <6.0% (42mmol/mol), being the reference. Average pre- and post-prandial results from an eight-point capillary glucose profile the previous day were categorised into 5 groups; the lowest (pre-prandial <5.0mmol/l, post-prandial <6.0mmol/l) being the reference.
RESULTS: An A1C of 6.0-6.4% (42-47mmol/mol) at 26 weeks' gestation was associated with a significantly increased risk of large for gestational age (LGA)(odds ratio 1.7 [95% CI 1.0-3.0]) and an A1C of 6.5-6.9% (48-52mmol/mol) with a significantly increased risk of pre-term delivery (odds ratio 2.5 [95% CI 1.3-4.8]), pre-eclampsia (4.3 [1.7-10.8]), need for a neonatal glucose infusion (2.9 [1.5-5.6]) and a composite adverse outcome (3.2 [1.3-8.0]). These risks increased progressively with increasing A1C. Results were similar at 34 weeks' gestation. Glucose data showed less consistent trends, although. the risk of a composite adverse outcome increased with pre-prandial glucose levels between 6.0-6.9mmol/l at 34 weeks (3.3[1.3-8.0]).
CONCLUSIONS: LGA increased significantly with an A1C ≥6.0 (42mmol/mol) at 26 and at 34 weeks gestation and with other adverse outcomes with an A1C≥ 6.5% (48mmol/mol). The data suggest that there is clinical utility in regular measurement of A1C during pregnancy.
Authors:
Michael J A Maresh; Valerie A Holmes; Christopher C Patterson; Ian S Young; Donald W M Pearson; James D Walker; David R McCance;
Related Documents :
25276234 - Association of adipokines, leptin/adiponectin ratio and c-reactive protein with obesity...
16753044 - The central issue? visceral fat mass is a good marker of insulin resistance and metabol...
10337854 - Relation of beta3-adrenergic receptor gene mutation to total body fat but not percent b...
25425394 - Low within- and between-day variability in exposure to new insulin glargine 300 u.ml(-1.)
25275984 - Diabetic myonecrosis: likely an underrecognized entity.
17361034 - Rosiglitazone induces mitochondrial biogenesis in mouse brain.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-3
Journal Detail:
Title:  Diabetes care     Volume:  -     ISSN:  1935-5548     ISO Abbreviation:  Diabetes Care     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-11-4     Completed Date:  -     Revised Date:  2014-11-5    
Medline Journal Info:
Nlm Unique ID:  7805975     Medline TA:  Diabetes Care     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Non-randomized confirmatory trial of modified radical hysterectomy for patients with tumor diameter ...
Next Document:  CD247, a Novel T Cell-Derived Diagnostic and Prognostic Biomarker for Detecting Disease Progression ...